XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Condensed Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current Assets    
Cash and cash equivalents (Note 6) $ 2,460.2 $ 2,818.6
Short-term investments (Note 6) 126.1 109.1
Accounts receivable, net of allowances of $14.3 (2024) and $14.8 (2023) 7,885.6 9,090.5
Other receivables 2,127.9 2,245.7
Inventories (Note 5) 6,101.8 5,772.8
Prepaid expenses 6,348.6 5,540.8
Other current assets 138.6 149.5
Total current assets 25,188.8 25,727.0
Investments (Note 6) 3,086.9 3,052.2
Goodwill 4,939.6 4,939.7
Other intangibles, net 6,762.2 6,906.6
Deferred tax assets 5,633.9 5,477.3
Property and equipment, net of accumulated depreciation of $11,235.0 (2024) and $11,099.3 (2023) 13,624.0 12,913.6
Other noncurrent assets 4,708.1 4,989.9
Total assets 63,943.5 64,006.3
Current Liabilities    
Short-term borrowings and current maturities of long-term debt 1,651.5 6,904.5
Accounts payable 2,473.7 2,598.8
Employee compensation 844.2 1,650.4
Sales rebates and discounts 9,429.6 11,689.0
Dividends payable 0.0 1,169.2
Other current liabilities 4,199.1 3,281.3
Total current liabilities 18,598.1 27,293.2
Noncurrent Liabilities    
Long-term debt 24,559.9 18,320.8
Accrued retirement benefits (Note 8) 1,427.9 1,438.8
Long-term income taxes payable 4,189.4 3,849.2
Other noncurrent liabilities 2,270.8 2,240.6
Total noncurrent liabilities 32,448.0 25,849.4
Commitments and Contingencies (Note 9)
Eli Lilly and Company Shareholders' Equity    
Common stock 594.2 593.6
Additional paid-in capital 7,009.5 7,250.4
Retained earnings 12,553.9 10,312.3
Employee benefit trust (3,013.2) (3,013.2)
Accumulated other comprehensive loss (Note 10) (4,299.5) (4,327.0)
Cost of common stock in treasury (32.7) (44.2)
Total Eli Lilly and Company shareholders' equity 12,812.2 10,771.9
Noncontrolling interests 85.2 91.8
Total equity 12,897.4 10,863.7
Total liabilities and equity $ 63,943.5 $ 64,006.3